Literature DB >> 8207459

The effect of oral anticoagulant therapy on APTT results from a bedside coagulation monitor.

M J Ray1, P A Carroll, S J Just, G A Hawson, J H Bett.   

Abstract

OBJECTIVE: The Ciba Corning 512 coagulation monitor (CC512) can be used to monitor heparin therapy by performing an activated partial thromboplastin time (APTT) at the patient's bedside. This study was designed to compare the CC512 results to results using the laboratory system. The relative sensitivities of both systems to the effect of oral anticoagulant therapy also was investigated.
METHODS: Activated partial thromboplastin times were performed with both the CC512 and laboratory system on 74 specimens from patients receiving i.v. heparin therapy, and on 14 specimens from patients on warfarin only. Heparin assays were performed on 43 of the specimens from the heparinized patients.
RESULTS: When a patient was receiving heparin only, the APTT results of the CC512 proved to be similar to existing laboratory methods. The CC512 APTT results of patients on warfarin only were markedly prolonged, whereas the laboratory APTTs were only slightly affected.
CONCLUSION: The CC512 results were comparable to the laboratory system. However, the CC512 APTT was more sensitive to the effect of warfarin than the laboratory APTT system used in this study. CC512 APTT results on a patient receiving both oral and intravenous anticoagulation could be misleading.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207459     DOI: 10.1007/bf02886821

Source DB:  PubMed          Journal:  J Clin Monit        ISSN: 0748-1977


  8 in total

1.  An artefact related to the ratio of sample volume to the blood collection vial size which effects the APTTs of specimens taken to monitor heparin therapy.

Authors:  M J Ray
Journal:  Thromb Haemost       Date:  1991-09-02       Impact factor: 5.249

2.  Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy.

Authors:  J Ansell; C Tiarks; J Hirsh; W McGehee; D Adler; R Weibert
Journal:  Am J Clin Pathol       Date:  1991-02       Impact factor: 2.493

3.  A comparison of two APTT reagents which use silica activators.

Authors:  M J Ray; G A Hawson
Journal:  Clin Lab Haematol       Date:  1989

4.  The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer.

Authors:  A M Shojania; J Tetreault; G Turnbull
Journal:  Am J Clin Pathol       Date:  1988-01       Impact factor: 2.493

5.  Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture.

Authors:  G Contant; M Gouault-Heilmann; J L Martinoli
Journal:  Thromb Res       Date:  1983-07-15       Impact factor: 3.944

6.  Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.

Authors:  A M van den Besselaar; J Meeuwisse-Braun; R Jansen-Grüter; R M Bertina
Journal:  Thromb Haemost       Date:  1987-04-07       Impact factor: 5.249

7.  Influence of whole blood on standard curve for heparin measurement--possible heparin binding by red cells.

Authors:  E Melissari; C Thye; M F Scully; V V Kakkar
Journal:  Thromb Haemost       Date:  1989-04-25       Impact factor: 5.249

8.  Variation among commercial activated partial thromboplastin time reagents in response to heparin.

Authors:  G A Shapiro; S W Huntzinger; J E Wilson
Journal:  Am J Clin Pathol       Date:  1977-05       Impact factor: 2.493

  8 in total
  1 in total

Review 1.  The role of point-of-care anticoagulation monitoring in arterial and venous thromboembolic disorders.

Authors:  C R Zimmerman
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.